MedTrace Logo

Two Doses of Dexmedetomidine as Adjuvent to Bupivacaine in Tap Block

NCT06624319 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2024-10-03

No results posted yet for this study

Summary

The aim of this study to determine the optimal dose of dexmedetomidine as an adjuvant to bupivacaine in U.S guided TAP block for preemptive analgesia In patients undergoing lower abdominal cancer surgeries.

Conditions

  • Post Operative Pain

Interventions

DRUG

Dexmedetomidine as adjuvent to bupvacaine in tap block

The analgesic effect of Two different doses of dexmedetomidine as adjuvent to bupivacaine in tap block

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Kerolos S Tawfeek · Assiut University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-31
Primary Completion
2026-01-31
Completion
2026-02-28

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06624319 on ClinicalTrials.gov